Your email has been successfully added to our mailing list.

×
0 0 0 0 0 0 0 0
Stock impact report

Q32 Bio: High-Risk, High-Reward With Bempikibart And ADX-097 [Seeking Alpha]

Q32 Bio Inc. (QTTB) 
Company Research Source: Seeking Alpha
Q32 Bio's Bempikibart and ADX-097 are in Phase 2 trials, targeting autoimmune and inflammatory diseases, with significant potential to address unmet medical needs. The company's unique approach of localized inhibition minimizes side effects and enhances efficacy, differentiating it in the biotech sector. Despite a short cash runway, Q32 Bio's recent merger, strategic reacquisition, and $42 million private placement bolstered its financial position. I rate Q32 Bio as a speculative "Buy" due to the promising drug candidates, but caution about potential dilution and research setbacks. DariaRen/iStock via Getty Images Q32 Bio Inc. ( NASDAQ: QTTB ) is a biotechnology company that develops therapies for immune-mediated conditions. The company targets the dysregulation of the immune system's innate and adaptive components to restore balance and treat various autoimmune and inflammatory diseases. Currently, QTTB's pipeline includes two key drug candidates in Phase 2 clinical trials Show less Read more
Impact Snapshot
Event Time:
QTTB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for
QTTB alerts

from News Quantified
Opt-in for
QTTB alerts

from News Quantified